Multi-omics program to understand complications and outcomes after aneurysmal subarachnoid hemorrhage
Aneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program (aSAH-Omics) ：A Multicenter Clinical and Mechanistic Study
This project will test if combining blood, cerebrospinal fluid, urine, imaging, and multi-omics data can find biomarkers that predict complications and outcomes in adults with aneurysmal subarachnoid hemorrhage.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Beijing Tiantan Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT07270419 on ClinicalTrials.gov |
What this trial studies
This multicenter observational project collects blood, cerebrospinal fluid, urine, and other biospecimens from adults with confirmed aneurysmal subarachnoid hemorrhage whose aneurysm is secured within 72 hours. Genomic, transcriptomic, proteomic, metabolomic, and imaging-omic profiling will be performed and integrated with detailed clinical and imaging data. The analysis will link molecular signatures to secondary complications such as delayed cerebral ischemia and pneumonia and to longer-term neurological outcomes. Results aim to identify pathways and biomarkers that explain outcome differences and support development of predictive tools or targeted interventions.
Who should consider this trial
Good fit: Adults (≥18 years) with confirmed aneurysmal subarachnoid hemorrhage who have had their aneurysm secured by clipping or coiling within 72 hours and can provide biospecimens and informed consent are ideal candidates.
Not a fit: Patients with non-aneurysmal or traumatic SAH, prior aneurysm surgery/embolization, active malignancy or severe hepatic/renal dysfunction, unstable cardiorespiratory status, pregnancy, or inability/unwillingness to provide required specimens are unlikely to benefit.
Why it matters
Potential benefit: If successful, this could provide biomarkers to identify patients at high risk for post-rupture complications and help guide earlier, more personalized care.
How similar studies have performed: Previous single-omics biomarker studies in aSAH have identified candidate markers, but integrated, multicenter multi-omics approaches like this are largely novel and unproven.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adult patients aged ≥18 years; 2. Confirmed diagnosis of aneurysmal subarachnoid hemorrhage (aSAH) by CTA, or DSA; 3. Aneurysm secured by either microsurgical clipping or endovascular coiling during hospitalization; 4. Time from onset to aneurysm treatment ≤ 72 hours; 5. Availability of biospecimens, including blood, cerebrospinal fluid (CSF), urine, or fecal samples collected during hospitalization; 6. Signed informed consent obtained from the patient or legal representative. Exclusion Criteria: 1. History of previous intracranial aneurysm surgery or embolization; 2. Non-aneurysmal SAH, traumatic SAH, or perimesencephalic non-aneurysmal hemorrhage; 3. Presence of malignancy, severe hepatic or renal dysfunction, or other systemic diseases that may affect survival or biomarker expression; 4. Severe cardiorespiratory insufficiency or unstable medical condition precluding study participation; 5. Pregnancy or lactation; 6. Refusal to participate or withdrawal of consent.
Where this trial is running
Beijing, Beijing Municipality
- Beijing Tiantan Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Runting Li, MD
- Email: tt18080lrt@163.com
- Phone: +86 15753166690
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.